Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The effect of neo-adjuvant chemotherapy on survival of patients with thoracic esophageal
squamous cell carcinomas remains the most controversial part of neo-adjuvant therapy for
esophageal carcinomas. One of our objectives is to evaluate whether the neo-adjuvant therapy
with cisplatin and paclitaxel followed by right thoracic approach esophagectomy with total
2-field lymph node dissection improves the overall survival of thoracic esophageal cancer
patients.
Phase:
Phase 3
Details
Lead Sponsor:
Henan Cancer Hospital
Collaborators:
Beijing Cancer Hospital Cancer Institute and Hospital, Chinese Academy of Medical Sciences Hunan Province Tumor Hospital Sun Yat-sen University Tianjin Medical University Cancer Institute and Hospital